Dr. David N. Oubre, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
15752 Medical Arts Plaza, Suite 101
Hammond, LA 70403
Who else practices at this address →
Tangipahoa Parish is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- Louisiana State University School of Medicine in New Orleans (1994)
- Years since graduation
- 32
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 481
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1994Medical school: Louisiana State University School of Medicine in New Orleans
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
LA license 022330
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- East Jefferson General Hospital Metairie, LA
- St Tammany PArish Hospital Covington, LA
- North Oaks Medical Center Hammond, LA
- Hood Memorial Hospital Amite, LA
- St Helena PArish Hospital Greensburg, LA
Medical groups
- Pontchartrain Cancer Center Inc (4 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 481
- Services billed
- 201,607
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, ferric carboxymaltose, 1 mg | 29,250 | 15 |
| Injection, denosumab, 1 mg | 6,060 | 23 |
| Injection, granisetron hydrochloride, 100 mcg | 1,800 | 27 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,224 | 24 |
| Established patient office or other outpatient visit, 30-39 minutes | 929 | 319 |
| Administration of chemotherapy into vein, 1 hour or less | 408 | 45 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 219 | 37 |
| Injection of additional new drug or substance into vein | 216 | 29 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 174 | 71 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 168 | 29 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Hammond, LA | 215 |
| Tamoxifen Citrate Other prescribers in Hammond, LA | 72 |
| Imatinib Mesylate | 69 |
| Abiraterone Acetate | 63 |
| Hydroxyurea Other prescribers in Hammond, LA | 60 |
| Eliquis (apixaban) Other prescribers in Hammond, LA | 57 |
| Gabapentin Other prescribers in Hammond, LA | 55 |
| Imbruvica (ibrutinib) | 51 |
| Lenalidomide | 51 |
| Dexamethasone Other prescribers in Hammond, LA | 50 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 48 companies reported 143 payments worth $7,477 in total to this clinician.
| AbbVie Inc. | $2,867 |
|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $1,401 |
| Asd Specialty Healthcare, LLC | $247 |
| Pharmaessentia USA Corporation | $222 |
| Novartis Pharmaceuticals Corporation | $212 |
| Astellas Pharma US Inc | $182 |
| AstraZeneca Pharmaceuticals LP | $159 |
| Daiichi Sankyo Inc. | $159 |
| Consulting Fee | $4,063 |
|---|---|
| Food and Beverage | $3,307 |
| Education | $107 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Apr 21, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $2,750 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 28, 2025 | Consulting Fee | $1,313 |
| Daiichi Sankyo Inc. Mar 21, 2025 | Education Enhertu · ONCOLOGY · in-kind | $99.99 |
| AstraZeneca Pharmaceuticals LP Jan 8, 2025 | Education ENHERTU · Oncology · in-kind Company’s descriptionJournal Article | $6.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 13 industry-funded studies in 2025, from 11 companies. The companies reported $250,358 in research payments for these studies, mostly to the institutions running them.
- A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT05514054 - A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
Beone Medicines USA, Inc. · Active, not recruiting · NCT05609370 - A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Genzyme Corporation · Active, not recruiting · NCT06356571 - Artemide Lung02 a phase III global study of rilvegostomig or pembrolizumab for patients with metastatic squamous non small cell lung cancer
AstraZeneca Pharmaceuticals LP - A Post-authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusionrelated Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous)
Janssen Research & Development, LLC - Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Mirati Therapeutics, Inc. · Recruiting · NCT04613596 - Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC
Genentech, Inc. - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry. The purpose of the Connect Myeloid disease registry is to provide unique insights into treatm…
Celgene Corporation - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
AbbVie Inc. · Active, not recruiting · NCT04401748 - An observational,prospective,multicenter study of non small cell lung cancer patients in the US receiving standard of care and initiating an approved therapy with risk of pneumonitis ILD
AstraZeneca UK Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.